introduction
Colorectal cancer (CRC) is the third commonest cancer in both males and females and second most common cause of cancer death [1] . About one-third to one-fourth of patients present initially with inoperable or metastatic disease. During treatment of advanced CRC, disease is monitored with clinical, radiological [computed tomography (CT)] and laboratory means [carcinoembryonic antigen (CEA)]. CEA is a glycoprotein which functions as an intracellular adhesion molecule and promotes cellular aggregation [2] . Overexpression of CEA at the basolateral surface of colon cancer cells may contribute to disruption of normal intracellular and cell-collagen bonds facilitating disordered histological architecture and cellular emigration or metastases [3] .
Currently, the American Society of Clinical Oncology guidelines for the use of tumour markers in gastrointestinal cancers recommended CEA to be the marker of choice in CRC for monitoring disease response to chemotherapy and that constantly increasing CEA levels should prompt investigations [4] . In contrast to the previous recommendations in 2000 indicating that two CEA values above baseline are adequate to document disease progression, it was accepted later in 2006 that initial transient CEA rise (flare) can be seen in patients receiving chemotherapy in the first 4-6 weeks of treatment, especially with oxaliplatin [4] . This statement was on the basis of two small studies which evaluated the CEA flare phenomenon and showed that CEA flare (defined as a >20% rise from baseline followed by a >20% drop from baseline in one or more subsequent CEA tests) may occur in 10%-15% of patients with metastatic disease treated with chemotherapy [5, 6] . It was also reported in these small series with 25 and 87 patients, respectively, that CEA flare was associated with favourable objective response to treatment. Its impact on survival is, however, currently unknown.
In our study, we aim to evaluate the incidence of CEA flare and its impact on objective response rate (ORR), progressionfree survival (PFS) and overall survival (OS) in patients receiving first-line chemotherapy for advanced CRC.
patients and methods
This study was approved by our Institutional Review Board. Eligibility criteria for our study included age ‡18 years, histological diagnosis of advanced colorectal adenocarcinoma considered for first-line chemotherapy at our institution from January 2000 to February 2008, baseline CEA and baseline radiological imaging (CT scan of chest, abdomen and pelvis 6 magnetic resonance imaging) available within 4 weeks from start of chemotherapy, a minimum of two cycles of chemotherapy, serial regular CEA assessment during treatment (two or more measurements at least once per month) and radiological imaging during treatment. Previous adjuvant chemotherapy was allowed but no neoadjuvant chemoradiotherapy or chemotherapy unless for metastatic or inoperable disease.
Patients were identified from our hospital electronic patient record (EPR) and pharmacy database which comprised all patients who received treatment at the Royal Marsden Hospital. Details of patients' demographics, site of primary, sites of metastases, type of chemotherapy regimens, values and dates of baseline, trough and peak CEA, other laboratory and imaging results and dates of initiating and stopping chemotherapy were collected retrospectively. All case notes and investigation results from all patients were available in our hospital EPR system. Discrepancies were verified with patients' written notes if necessary and the database was appended accordingly.
CEA flare (F) was defined as a ‡15% rise from baseline (a minimum 4 lg/l rise was required) followed by subsequent ‡15% decrease from baseline. Serum CEA was analysed by an Abbott Architect i2000 system (Abbott Park, IL). Reference range for CEA in our institution was <3 lg/l in nonsmokers and <5 lg/l in smokers. Patients were divided into five groups according to baseline CEA levels and CEA kinetic during treatment: flare (F), decreasing (D), increasing (I), normal baseline (NB) and stable (S). Patients were categorised as normal baseline rather than CEA nonsecretor because a minority of these patients exhibited CEA rise in subsequent lines of therapy.
Patients were scheduled to have at least 6 months of chemotherapy in the absence of disease progression or intolerable toxic effects. Assessment of disease response was carried out by CT at least once every 12 weeks, or more frequently in the presence of clinical deterioration or as specified by specific trial protocols in which the patients might be participating. Disease progression was on the basis of radiological criteria using the RECIST [7] . statistical considerations PFS was defined from the date of initiating first-line chemotherapy till disease progression, death or censored at last follow-up. OS was defined from the date of initiating first-line chemotherapy till death from any cause. Survival end points were estimated using the Kaplan-Meier method. We carried out univariate and multivariate logistic regression analyses to assess the impact of CEA kinetic and other established clinical determinants on ORR to first-line chemotherapy in advanced CRC. Univariate survival analyses using log-rank tests and multivariate forward-step Cox regression modelling were carried out to assess the prognostic impact of CEA kinetic and other established clinical determinants on PFS and OS. Factors with P < 0.05 in the univariate analysis were entered into the multivariate model. Apart from CEA kinetic groups, other clinical determinate factors included performance status (PS 0, 1 versus 2), metastatic site (liver/peritoneum versus others), number of tumour sites (1 versus 2 versus >2), primary tumour site (rectum versus colon), treatment (monotherapy versus combination chemotherapy versus targeted agent plus chemotherapy), alkaline phosphatase (ALP £300 versus >300 U/l), white cell count (WCC £10 versus >10 · 10 9 /l), haemoglobin (Hb £11 versus >11 g/l), platelets (£400 versus >400 · 10 9 /l) and lactate dehydrogenase [<upper limit of normal (ULN) versus >ULN]. Targeted agents included bevacizumab, cetuximab and panitumumab. Most of the above factors had been previously identified as independent prognostic factors [8, 9] . The first factor in each of these categories and increasing CEA in the CEA kinetic groups were used as control and their risk ratios (RRs) set at 1. For assessment of ORR, RR >1 indicated better response, whereas for PFS and OS, RR <1 indicated better survival. All efficacy end points were updated in November 2008 and analyses were carried out using SPSS package version 15 (SPSS Inc., Chicago, IL). Two-sided P values of <0.05 were considered significant for all end points and 95% confidence intervals (CIs) were quoted.
results
From January 2000 to February 2008, 837 patients diagnosed with advanced CRC were screened and 780 considered for first-line chemotherapy at our institution. Of those, 670 met our eligibility criteria. Reasons for ineligibility are outlined in Figure 1 . Figure 1 shows the incidence of each CEA kinetic group in our study population. Seventy-eight of 670 (11.6%) patients demonstrated the CEA flare phenomenon. The median baseline CEA value in the flare group was 74 lg/l (range 5-31 480 lg/l) and the median peak CEA value was 115 lg/l, reached in 21 days (range 4-61 days). The median duration of CEA flare (from date of baseline CEA to date of first CEA level below the baseline) was 49 days (range 16-117 days). Table 1 shows the patients' baseline demographic details. Thirteen percent of patients receiving oxaliplatin-based chemotherapy and 11% of patients receiving irinotecan-based chemotherapy had CEA flare. Table 2 shows the sites of metastases. Less number of patients of NB group were diagnosed with liver metastases (45%) compared with groups F (74%), D (75%) and I (66%), but more with lung metastases (33% versus 15%, 22% and 23% accordingly). It is also noteworthy that patients of I group were more likely to have peritoneal disease (32%) or more than one metastatic site (45%) than those of the other groups. Table 3 shows the best achieved ORR observed in the various CEA kinetic groups. The ORR for the whole cohort was 55.2%. Table 4 shows the multivariate analyses results for ORR, PFS and OS. PS 0 or 1, combination therapy (6targeted therapy) and CEA kinetic were significant predictors for better response. Compared with increasing CEA, all the other CEA kinetic groups had a significantly better chance of response with the highest chance of response in the CEA flare group.
At the time of analysis, 580 (87%) patients had progressed and 408 (61%) patients had died. The median follow-up for surviving patients was 20.3 months. Figure 2 shows the PFS of patients according to the CEA kinetic groups with their respective median PFS and 1-year PFS rates. Highly significant differences in PFS were seen among these groups (P < 0.001). On multivariate analysis (Table 4) , CEA kinetic remained as a significant prognostic factor for PFS. CEA flare was associated with a 62% relative reduction in the risk of progression compared with increasing CEA (RR: 0.38; 95% CI: 0.26-0.56). Other established clinical determinants, including PS, metastatic sites, number of tumour sites, ALP, WCC and Hb, were shown to be significantly prognostic for PFS in our cohort of patients. Figure 3 shows the OS of patients according to the CEA kinetic groups with their respective median OS, 1-and 2-year OS rates. Similar to PFS, highly significant differences in OS were seen among the five groups (P < 0.001). On original article Annals of Oncology multivariate analysis (Table 4) , CEA kinetic again was a significant prognostic factor for OS. CEA flare was associated with a nearly halving of the risk of death compared with increasing CEA (RR: 0.53; 95% CI: 0.34-0.82). Aside from metastatic site, all other clinical determinants significantly prognostic for PFS were also significantly prognostic for OS.
However, patients with normal baseline CEA appeared to fare most favourably for both PFS (RR: 0.27; 95% CI: 0.19-0.38) and OS (RR: 0.32; 95% CI: 0.21-0.49). These patients enjoyed a median OS of 36.5 months. Compared with patients receiving first-line monotherapy, those who had combination chemotherapy 6 targeted therapy were found to have significantly improved ORR (P < 0.001) and PFS (P = 0.009), but not OS (P = 0.544) on univariate analysis.
discussion
To our knowledge, this is the largest report on CEA flare in patients with advanced CRC during first-line chemotherapy. Previous small series indicated a correlation between CEA flare and improved tumour response. However, our sample size-nearly eightfold more than the largest published series so far-allowed us to investigate the relationship between CEA kinetic and tumour response as well as, more importantly, survival. We showed that CEA flare was an independent favourable predictive and prognostic factor for ORR, PFS and OS, compared with rising CEA. CEA flare phenomenon observed within a median of 3 weeks predicted radiological response at 12 weeks. Aside from CEA flare, decreasing and normal baseline CEA were also associated with better ORR, PFS and OS. The incidence of CEA flare in our study was similar to that in others [5, 6] . Although the definition of CEA flare used in our study was slightly different (615% change from baseline CEA versus 620% in other series), we also set a minimum rise of at least 4 lg/l rise of CEA to make the data more robust. Indeed, if we had applied the 620% criteria, without the minimum 4 lg/l change used in our study, the CEA flare incidence would have been 10.6% (instead of 11.6%) and the ORR would have increased to 75% (instead of 73% in our study). Therefore, the results are very similar to the previous definition of a flare phenomenon. Although CEA flare was previously reported to be associated with oxaliplatin/fluoropyrimidine chemotherapy, the incidence of CEA flare was relatively similar for patients receiving oxaliplatin-based chemotherapy (13%) and those receiving irinotecan-based chemotherapy (11%) in our study.
In our study, we defined an increasing CEA as the control group, on the basis of the general consensus and published evidence that constantly increasing CEA values are related to disease progression [3] . Rather than signifying worsening of disease status, we showed that CEA flare was associated with a high response rate, numerically highest compared with the other favourable groups. We also showed for the first time that CEA flare, decreasing and normal baseline CEA groups were all associated with significantly prolonged PFS and OS than increasing CEA group. As the number of patients with stable CEA was small, the confidence level on the survival benefit was wider.
Although patients with normal baseline CEA appeared to have the best PFS and OS among all the CEA kinetic groups, to minimize multiple statistical testing, we did not perform pairwise comparisons among different groups. Rather we chose to show the relative survival effect in a Cox regression model, correcting for other significant covariates. In particular, CEA flare and decreasing CEA had similar RR for ORR, PFS and OS. Although our study utilised clinical and laboratory data collected retrospectively in a single institution, treatment approach and follow-up were broadly similar during this study period. Our data were consistent with other published results from multicentre randomised controlled trials, reaffirming the (13) 11 (14) 32 (10) 14 (17) 24 (15) (9) 6 (8) 27 (8) 6 (7) 11 (7) 4 (5) 26 (8) 51 (61) 11 (7) 11 (32) 104 (16) CEA; carcinoembryonic antigen; F, CEA flare; D, decreasing CEA; I, increasing CEA; NB, normal baseline CEA; S, stable CEA; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CI, confidence interval.
original article Annals of Oncology ability to generalise our data to routine clinical practice. We confirmed PS, number of metastatic sites, ALP, WCC and Hb to be significant prognostic factors for survival [8, 9] . Similar to other published studies [10] [11] [12] , patients treated with combination first-line chemotherapy in our study had a significant ORR and PFS than those treated with monotherapy, but without significant improvement in OS.
The exact mechanisms of how different CEA kinetic resulted in varying outcome are currently unknown. Better tumour response and survival associated with decreasing CEA might conceivably be due to decreasing tumour burden. However, this did not explain why CEA flare or normal baseline CEA would have a better treatment outcome. It is possible that other properties of this antigen may be involved in the tumour CEA is a glycoprotein normally found in embryonic colonic tissue and in colon adenocarcinoma but not in healthy normal adult tissues [3] . Genes encoding for the CEA protein (20-30 genes, located on chromosome 19) belong to the immunoglobulin genes superfamily which also includes genes encoding for adhesion molecules-intracellular adhesion molecule-1 and -2 and lymphocyte function-associated antigen and the major histocompatibility antigens [13] . CEA has been indicated to facilitate colon cancer cells aggregation and tumour progression and/or metastasis [2, 3] . There is evidence from preclinical models that systemic injection of CEA protein in athymic nude mice transplanted with various CRC cells lines, with different metastatic potential, enhanced the incidence of liver metastases from 2% to 48% in a dose-dependent manner. However, CEA-driven metastases were observed mainly in the CRC model with weak metastatic potential but not in the nonmetastatic or the highly metastatic mice models [14] , indicating that CEA might act as an attachment factor enhancing the metastatic potential in weakly metastatic tumours but does not make non-metastatic tumours metastatic or highly metastatic tumours more aggressive. It might be possible that higher serum CEA levels promote disease progression and metastasis rather than original article Annals of Oncology simply reflect a tumour burden increase. The above hypothesis may also explain why rising CEA might precede any radiological tumour detection with the existing conventional means and why decreasing (directly or after flare) and normal levels of CEA were associated with improved PFS and OS in our study.
With regard to the mechanism of CEA flare, there have been a few suggested theories. Some have implied that CEA flare was a result of tumour cell lysis (as observed in other malignancies with high tumour cell turnover); others implied that this might be secondary to liver toxicity allowing release of this antigen in the bloodstream or a delayed clearance of CEA. These theories did not explain why other signs or biochemical markers often seen in tumour lysis syndrome (such as high serum potassium, phosphate or urate) were not a consistent finding during the CEA flare period. Moreover, other biochemical parameters indicative of liver toxicity were not often seen. On the contrary, improved serum liver function tests were frequently observed during this period. Evidence from some preclinical studies indicated that treatment of various colon cancer cell lines with 5-fluorouracil (5-FU)-based chemotherapy increases the CEA messenger RNA transcription and expression and, therefore, may contribute to the initial CEA flare until reduction of tumour cells counteracts for this rise [15, 16] . The flare phenomenon was particularly pronounced when 5-FU was combined with a platinum agent or interferon gamma [16] [17] [18] .
It is important to note that our dataset was derived from all eligible patients treated at our single institution, both within and outside clinical trial settings. Whereas generally CEA was measured at the beginning of each cycle of chemotherapy, the cycle length might be different with individual treatment regimen. Furthermore, additional CEA measurement might be made if patient came up for additional visits for toxicity assessment in between cycles. Nevertheless, CEA kinetic would not be used as a sole criterion for treatment change without additional assessment, such as objective imaging or clinical status. However, CEA flare phenomenon is important for clinical trials in which CEA is measured where a 'differential response' could otherwise be stated.
In conclusion, CEA flare occurred in 11.6% of patients with advanced CRC on first-line chemotherapy. Compared with increasing CEA, flare, decreasing and normal baseline CEA during first-line chemotherapy were associated with better response-highest ORR with CEA flare (in univariate and multivariate analysis). Flare, decreasing and normal baseline CEA were also associated with significantly better PFS and OS. We confirmed PS, number of metastatic sites, WCC, Hb and ALP as significant prognostic factors for OS in advanced CRC. CEA should continue to be utilised as a useful marker for treatment monitoring in association with radiological imaging. Future guidelines need to recognize that flare is common in many fluoropyrimidine combination treatments, not only with oxaliplatin, and CEA flare is an independent favourable predictive and prognostic factor for treatment response and survival, compared with rising CEA. 
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